The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

Authors:   T. Yamamoto,K. Nakai,T. Nariai,H. Kumada,T. Okumura,M. Mizumoto,K. Tsuboi,A. Zaboronok,E. Ishikawa,H. Aiyama,K. Endo,T. Takada,F. Yoshida,Y. Shibata,A. Matsumura,
Journal: Applied Radiation and Isotopes
https://doi.org/10.1016/j.apradiso.2011.02.013
Abstract: The phase II trial has been prepared to assess the effectiveness of BPA (250mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75mg/m2) for the treatment of newly diagnosed GBM. BPA uptake is determined by 18F-BPA-PET and/or 11C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0Gy or less. Primary end point is overall survival.